PropertyValue
?:abstract
  • The rapid emergence of COVID-19 has sent shockwaves through healthcare systems globally, with cancer patients at increased risk. The interplay of the virus and host immune system has been implicated in the development of ARDS. Immunotherapy agents have the potential to adversely potentiate this phenomenon, requiring careful real-world observation.
?:creator
?:doi
  • 10.1038/s41416-020-0930-7
?:doi
?:journal
  • Br_J_Cancer
?:license
  • cc-by
?:pdf_json_files
  • document_parses/pdf_json/c1b34d713540c17b3b9d8ea84d8950179f573152.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7296191.xml.json
?:pmcid
?:pmid
?:pmid
  • 32546835.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome?
?:type
?:year
  • 2020-06-16

Metadata

Anon_0  
expand all